UnitedHealth HouseCalls Under DOJ Scrutiny: Impact on Stock and Industry

UnitedHealth Group is under scrutiny by the U.S. Department of Justice for potential Medicare Advantage billing practices. The investigation focuses on home visits that may have led to inflated diagnoses for higher payments. UnitedHealth denies wrongdoing and stands by its compliance with federal guidelines. The probe could have significant implications for the healthcare industry and UnitedHealth’s position as a major player in Medicare Advantage. Peers like Molina Healthcare and Centene Corporation are also struggling with rising medical costs, leading to earnings revisions. UnitedHealth’s stock has declined in 2025, with a forward P/E ratio of 12.82 and a Zacks Rank of #5 (Strong Sell).

Read more at Zacks Investment Research: Billing or Healing? UnitedHealth’s HouseCalls Get a DOJ Checkup – July 10, 2025